Currently out of the existing stock ratings of Catherine Novack, 47 are a BUY (97.92%), 1 are a HOLD (2.08%).

Catherine Novack

Work Performance Price Targets & Ratings Chart

Analyst Catherine Novack, currently employed at JONESTRADING, carries an average stock price target met ratio of 39.64% that have a potential upside of 79.99% achieved within 158 days.

Catherine Novack’s has documented 90 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CAPR, Capricor Therapeutics at 31-Jul-2026.

Wall Street Analyst Catherine Novack

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for WVE (WAVE LIFE SCIENCES LTD) at 9/3/2024. The price target of $12 was fulfilled within 43 days with a profit of $6.45 (116.22%) receiving and performance score of 27.03.

Average potential price target upside

DARE Dare Bioscience KZR Kezar Life Sciences ALDX Aldeyra The FEMY Femasys WVE Wave Life Sciences Ltd CAPR Capricor Therapeutics LRMR Larimar Therapeutics RGLS Regulus Therapeutics CRNX Crinetics Pharmaceuticals DYN Dyne Therapeutics  RLYB Rallybio Corp RZLT Rezolute PPBT Purple Biotech CALC CalciMedica, Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Show more analysts

Please expand the browser size to see the chart

Which stock is Catherine Novack is most bullish on?

Potential upside of $0.05 has been obtained for CRNX (CRINETICS PHARMACEUTICALS)

Which stock is Catherine Novack is most reserved on?

Potential downside of -$0 has been obtained for CAPR (CAPRICOR THERAPEUTICS)

What Year was the first public recommendation made by Catherine Novack?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?